P131 Patients with severe eosinophilic asthma achieved remission over 2 years with benralizumab: integrated analysis of the >1000-patient, multinational, real-world XALOC-1 study
Bibliographic record
Abstract
Background Biologic therapies have made clinical remission a viable goal in patients with severe eosinophilic asthma (SEA). Aim We describe clinical remission in patients with SEA, with/without prior biologic experience, over 2 years of benralizumab therapy in the large-scale, real-world, XALOC-1 study programme. Methods This analysis of retrospective, multi-national data assessed clinical remission rates over 2 years. Remission was defined as: exacerbation free during the entire follow-up period (48 or 96 weeks); asthma symptom control (Asthma Control Test score ≥16 or 6-item Asthma Control Questionnaire score <1.5) and no maintenance oral corticosteroid use, assessed at Week 48 or 96. Results Patients (n=1070) had a mean (SD) age of 55.2 (13.7) years; 58.7% were female; 61.9% were biologic-naïve and 37.8% -experienced (omalizumab 43.6%, mepolizumab, 62.6%, reslizumab, 8.2%). 45.1% of patients achieved remission by Week 48, 37.5% by Week 96 (figure 1). Of patients who met remission criteria at Week 96, 59.3% had sustained remission from Week 48. Remission rates were higher in biologic-naïve vs -experienced patients, and in omalizumab- vs mepolizumab-experienced patients, across all timepoints (figure 1). Conclusions Clinical remission is a realistic, sustainable goal up to 2 years for patients with SEA receiving benralizumab, regardless of prior biologic experience. Please refer to page A291 for declarations of interest related to this abstract.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".